drugset / Trial / NCT00358826
Study Effect of VIA-2291 on Vascular Inflammation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
Timeline
- Start
- 2006-07
- Primary completion
- 2008-08
- Completion
- 2008-09
Outcome
Met primary endpoint
registry analysis (superiority or other test); VIA-2291 25 mg vs Placebo; p <0.001; ANCOVA; note: Adjusted using Dunnett's method. NCT00358826 ↗
registry analysis (superiority or other test); VIA-2291 50 mg vs Placebo; p <0.001; ANCOVA; note: Adjusted using Dunnett's method. NCT00358826 ↗
registry analysis (superiority or other test); VIA-2291 100 mg vs Placebo; p <0.001; ANCOVA; note: Adjusted using Dunnett's method. NCT00358826 ↗
Publications
- Background Tardif JC, L'allier PL, Ibrahim R, Gregoire JC, Nozza A, Cossette M, Kouz S, Lavoie MA, Paquin J, Brotz TM, Taub R, Pressacco J. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. doi: 10.1161/CIRCIMAGING.110.937169. Epub 2010 Feb 27.
- Matsumoto S, Ibrahim R, Gregoire JC, L'Allier PL, Pressacco J, Tardif JC, Budoff MJ. Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. Clin Cardiol. 2017 Apr;40(4):210-215. doi: 10.1002/clc.22646. Epub 2016 Nov 24.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATRELEUTON | Small molecule | 25 mg | Oral |
| Subject | ATRELEUTON | Small molecule | 50 mg | Oral |
| Subject | ATRELEUTON | Small molecule | 100 mg | Oral |